These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 37442156)

  • 1. FXR Friend-ChIPs in the Enterohepatic System.
    Meadows V; Yang Z; Basaly V; Guo GL
    Semin Liver Dis; 2023 Aug; 43(3):267-278. PubMed ID: 37442156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders.
    Molinaro A; Marschall HU
    Biochem Soc Trans; 2022 Feb; 50(1):361-373. PubMed ID: 35191955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesoid X receptor: from medicinal chemistry to clinical applications.
    Fiorucci S; Mencarelli A; Distrutti E; Zampella A
    Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesoid X receptor modulators (2011 - 2014): a patent review.
    Sepe V; Distrutti E; Fiorucci S; Zampella A
    Expert Opin Ther Pat; 2015; 25(8):885-96. PubMed ID: 26183029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of farnesoid X receptor in cholestasis.
    Yuan ZQ; Li KW
    J Dig Dis; 2016 Aug; 17(8):501-509. PubMed ID: 27383832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis.
    Xiang D; Yang J; Liu L; Yu H; Gong X; Liu D
    Biomed Pharmacother; 2023 Dec; 168():115606. PubMed ID: 37812893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear receptor FXR, bile acids and liver damage: Introducing the progressive familial intrahepatic cholestasis with FXR mutations.
    Cariello M; Piccinin E; Garcia-Irigoyen O; Sabbà C; Moschetta A
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1308-1318. PubMed ID: 28965883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism.
    Zhou W; Anakk S
    Mol Cell Endocrinol; 2022 Jun; 549():111616. PubMed ID: 35304191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Picroside II protects against cholestatic liver injury possibly through activation of farnesoid X receptor.
    Li T; Xu L; Zheng R; Wang X; Li L; Ji H; Hu Q
    Phytomedicine; 2020 Mar; 68():153153. PubMed ID: 32018210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress.
    Wang MQ; Zhang KH; Liu FL; Zhou R; Zeng Y; Chen AL; Yu Y; Xia Q; Zhu CC; Lin CZ
    Phytomedicine; 2024 Jan; 122():155124. PubMed ID: 38014837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting FXR in Cholestasis.
    Keitel V; Dröge C; Häussinger D
    Handb Exp Pharmacol; 2019; 256():299-324. PubMed ID: 31201556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.
    Modica S; Petruzzelli M; Bellafante E; Murzilli S; Salvatore L; Celli N; Di Tullio G; Palasciano G; Moustafa T; Halilbasic E; Trauner M; Moschetta A
    Gastroenterology; 2012 Feb; 142(2):355-65.e1-4. PubMed ID: 22057115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
    Modica S; Moschetta A
    FEBS Lett; 2006 Oct; 580(23):5492-9. PubMed ID: 16904670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effects of SRT1720 via the HNF1α/FXR signalling pathway and anti-inflammatory mechanisms in mice with estrogen-induced cholestatic liver injury.
    Yu L; Liu X; Li X; Yuan Z; Yang H; Zhang L; Jiang Z
    Toxicol Lett; 2016 Dec; 264():1-11. PubMed ID: 27818225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease.
    Gadaleta RM; van Mil SW; Oldenburg B; Siersema PD; Klomp LW; van Erpecum KJ
    Biochim Biophys Acta; 2010 Jul; 1801(7):683-92. PubMed ID: 20399894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
    Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
    JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
    Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
    Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yangonin modulates lipid homeostasis, ameliorates cholestasis and cellular senescence in alcoholic liver disease via activating nuclear receptor FXR.
    Kong L; Dong R; Huang K; Wang X; Wang D; Yue N; Wang C; Sun P; Gu J; Luo H; Liu K; Wu J; Sun H; Meng Q
    Phytomedicine; 2021 Sep; 90():153629. PubMed ID: 34304130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hesperidin alleviates cholestasis via activation of the farnesoid X receptor in vitro and in vivo.
    Zhang G; Sun X; Wen Y; Shi A; Zhang J; Wei Y; Wu X
    Eur J Pharmacol; 2020 Oct; 885():173498. PubMed ID: 32841642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury.
    Petrescu AD; DeMorrow S
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.